Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses KALV in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named KALV in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Benjamin Palleiko | $580,441 | $389,138 | $5,486,659 | $302,468 | $0 | $0 | $13,491 | $6,772,197 |
| Chief Executive Officer | ||||||||
| Brian Piekos | 296,346 | 184,000 | 802,400 | 851,420 | 0 | 0 | 9,967 | 2,144,133 |
| Chief Financial Officer | ||||||||
| Paul Audhya | 502,900 | 221,276 | 1,097,159 | 0 | 0 | 0 | 12,639 | 1,833,974 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Benjamin Palleiko | $6,772,197 | $2,420,747 | — | +4,351,450 |
| Brian Piekos | 2,144,133 | — | — | — |
| Paul Audhya | 1,833,974 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Paul Audhya | OTHER | — | — | — | — | — | $1,938,200 |
| Benjamin Palleiko | OTHER | — | — | — | — | — | 3,731,160 |
| Brian Piekos | OTHER | — | — | — | — | — | 802,400 |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brian Piekos | RSU | 87,500 | — | $596,750 |
| Paul Audhya | Option | 6,988 | 9.28 | — |
| Benjamin Palleiko | Option | 33,750 | 24.23 | — |
| Benjamin Palleiko | Option | 47,354 | 8.39 | — |
| Paul Audhya | RSU | 65,000 | — | 759,850 |
| Paul Audhya | RSU | 12,084 | — | 82,413 |
| Benjamin Palleiko | Option | 33,800 | 7.07 | — |
| Benjamin Palleiko | Option | 105,000 | 10.2 | — |
| Brian Piekos | Option | 100,000 | 10.4 | — |
| Benjamin Palleiko | Option | 29,611 | 6.74 | — |
| Benjamin Palleiko | Option | 37,500 | 24.23 | — |
| Benjamin Palleiko | Option | 52,600 | 16.08 | — |
| Benjamin Palleiko | Option | 6,988 | 9.28 | — |
| Paul Audhya | RSU | 100,000 | — | 1,003,000 |
| Paul Audhya | RSU | 12,094 | — | 112,232 |
| Benjamin Palleiko | Option | 71,700 | 8.21 | — |
| Paul Audhya | Option | 2,084 | 24.97 | — |
We seek to ensure that the total compensation paid to our executive officers is reasonable and competitive. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-10-01 | 33,600,808 | 3,985,860 | 5,112 | 89.4% | Passed |
| 2024 | 2024-10-03 | 26,578,805 | 4,459,363 | 36,750 | 85.63% | Passed |
| 2023 | 2023-09-26 | 20,001,348 | 2,652,134 | 1,810 | 88.29% | Passed |
| 2022 | 2022-10-13 | 17,693,866 | 1,588,884 | 1,663 | 91.76% | Passed |
| 2021 | 2021-09-30 | 19,696,080 | 2,450,450 | 526 | 88.94% | Passed |
| 2020 | 2020-10-01 | 10,399,572 | 660,300 | 108,485 | 94.03% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-10-01 | 89.4%a |
| 2024 | 2024-10-03 | 85.63%b |
| 2023 | 2023-09-26 | 88.29%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted to determine whether a nominee receives a majority of votes cast.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted to determine whether a nominee receives a majority of votes cast.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted to determine whether a nominee receives a majority of votes cast.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Brian J. G. PereiraIndependent · Board Chair · Audit · Nominating/Governance | $87,500 | $0 | $83,206 | $0 | $0 | $170,706 |
| Edward W. UnkartIndependent · Audit (Chair) | 62,500 | 0 | 83,206 | 0 | 0 | 145,706 |
| Nancy StuartIndependent · Audit · Nominating/Governance (Chair) | 62,500 | 0 | 83,206 | 0 | 0 | 145,706 |
| Laurence ReidIndependent · Nominating/Governance | 18,363 | 0 | 124,137 | 0 | 0 | 142,500 |
| Patrick TreanorIndependent · Compensation (Chair) | 54,341 | 0 | 83,206 | 0 | 0 | 137,547 |
| William FaireyIndependent · Compensation | 50,000 | 0 | 83,206 | 0 | 0 | 133,206 |
| Benjamin L. PalleikoEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $42,500 |
|---|---|
| Annual equity retainer | $83,206 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $335,204 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $335,204 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | KalVista Pharmaceuticals, Inc. | 2024 | Benjamin Palleiko | $580,441 | $5,486,659 | $302,468 | $0 | $6,772,197 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Benjamin Palleiko | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “Summary Compensation Table”. As printed: 6,772,197. Filing ↗machine: span 291290–291299 |
| 2 | Section 01, Brian Piekos | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “Summary Compensation Table”. As printed: 2,144,133. Filing ↗machine: t76 · r5 · c25 · span 296302–296311 |
| 3 | Section 01, Paul Audhya | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “Summary Compensation Table”. As printed: 1,833,974. Filing ↗machine: span 299360–299369 |
| 4 | Section 03, Paul Audhya OTHER | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t76 · r7 · c13 · span 298656–298665 |
| 5 | Section 03, Benjamin Palleiko OTHER | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t76 · r2 · c13 · span 290586–290595 |
| 6 | Section 03, Brian Piekos OTHER | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t76 · r5 · c13 · span 295638–295645 |
| 7 | Section 08, Brian J. G. Pereira | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “Director Compensation”. As printed: 170,706. Filing ↗machine: t66 · r4 · c11 · span 250069–250076 |
| 8 | Section 08, Edward W. Unkart | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “Director Compensation”. As printed: 145,706. Filing ↗machine: t66 · r12 · c11 · span 254556–254563 |
| 9 | Section 08, Nancy Stuart | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “Director Compensation”. As printed: 145,706. Filing ↗machine: t66 · r8 · c11 · span 252310–252317 |
| 10 | Section 08, Laurence Reid | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “Director Compensation”. As printed: 142,500. Filing ↗machine: t66 · r6 · c11 · span 251203–251210 |
| 11 | Section 08, Patrick Treanor | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “Director Compensation”. As printed: 137,547. Filing ↗machine: t66 · r10 · c11 · span 253445–253452 |
| 12 | Section 08, William Fairey | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “Director Compensation”. As printed: 133,206. Filing ↗machine: t66 · r2 · c11 · span 248955–248962 |
| 13 | Section 08, Benjamin L. Palleiko | DEF 14A | 2025-08-21 | 0001193125-25-185353 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 06, 2025 vote | Form 8-K | 2025-10-02 | 0001193125-25-227478 | Item 5.07 · say-on-pay result. As reported: 89.4% (votes for as printed: 33,600,808). Filing ↗ |
| 15 | Section 06, 2024 vote | Form 8-K | 2024-10-04 | 0000950170-24-112904 | Item 5.07 · say-on-pay result. As reported: 85.63% (votes for as printed: 26,578,805). Filing ↗ |
| 16 | Section 06, 2023 vote | Form 8-K | 2023-09-28 | 0000950170-23-050440 | Item 5.07 · say-on-pay result. As reported: 88.29% (votes for as printed: 20,001,348). Filing ↗ |
| 17 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 18 | Section 09b board cost (computed) | Computed | — | computed | Cash 335,204 + equity 0 + all other 0 = 335,204, summed across the director compensation table rows.machine: formula: Σ = 335,204 |
| 19 | KalVista Pharmaceuticals, Inc. (subject), Section 10b CEO total | DEF 14A | 2025-08-21 | 0001193125-25-185353 | CEO total compensation as printed in KalVista Pharmaceuticals, Inc.'s own proxy. As printed: 6,772,197. Filing ↗machine: span 291290–291299 |